EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies

Daoyuan Huang iD, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K Simon iD, Wenyi Wei

Biomolecules · 2025

DOI: 10.3390/biom15020237 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Daoyuan Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Neoplasms, Signal Transduction, Ubiquitination, Poly ADP Ribosylation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, National institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly(ADP-ribosyl)ation (PARylation) is a dynamic protein post-translational modification (PTM) mediated by ADP-ribosyltransferases (ARTs), which regulates a plethora of essential biological processes, such as DNA repair, gene expression, and signal transduction. Among these, PAR-dependent ubiquitination (PARdU) plays a pivotal role in tagging PARylated substrates for subsequent ubiquitination and degradation events through the coordinated action of enzymes, including the E3 ligase RNF146 and the ADP-ribosyltransferase tankyrase. Notably, this pathway has emerged as a key regulator of tumorigenesis, immune modulation, and cell death. This review elucidates the molecular mechanisms of the PARdU pathway, including the RNF146–tankyrase interaction, substrate specificity, and upstream regulatory pathways. It also highlights the biological functions of PARdU in DNA damage repair, signaling pathways, and metabolic regulation, with a focus on its therapeutic potential in cancer treatment. Strategies targeting PARdU, such as tankyrase and RNF146 inhibitors, synthetic lethality approaches, and immune checkpoint regulation, offer promising avenues for precision oncology. These developments underscore the potential of PARdU as a transformative therapeutic target in combating various types of human cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsSignal TransductionUbiquitinationPoly ADP RibosylationHumansTankyrasesUbiquitin-Protein LigasesAnimalsDNA RepairProtein Processing, Post-Translational

Stichwörter der Autor:innen

PARylation ubiquitinationRNF146tankyrase

Substanzen

TankyrasesUbiquitin-Protein LigasesRNF146 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

ORCID-Profile: Daoyuan Huang, David K Simon

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • National institute of Health
  • NIH

Zitieren

APA

Huang, D., Wang, J., Chen, L., Jiang, W., Inuzuka, H., Simon, D. K., & Wei, W. (2025). Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies. Biomolecules. https://doi.org/10.3390/biom15020237

Vancouver

Huang D, Wang J, Chen L, Jiang W, Inuzuka H, Simon DK, et al. Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies. Biomolecules. 2025. doi:10.3390/biom15020237

BibTeX
@article{Huang2025,
  author = {Huang, Daoyuan and Wang, Jingchao and Chen, Li and Jiang, Weiwei and Inuzuka, Hiroyuki and Simon, David K and Wei, Wenyi},
  title = {Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15020237}
}
Kostenlos starten →